Literature DB >> 14742913

Differential coupling of the PAC1 SV1 splice variant on human colonic tumors to the activation of intracellular cAMP but not intracellular Ca2+ does not activate tumor proliferation.

Patrizia M Germano1, Sang V Le, David S Oh, Robert Fan, Sandy Lieu, Alan Siu, Joseph R Pisegna.   

Abstract

PAC1 is a recently cloned and characterized heptahelical, G protein-coupled receptor with high affinity to PACAP-27 and PACAP-38 and is differentially coupled to activate intracellular Ca2+ and cAMP. PAC1 is expressed as four major splice variants, each possessing differential coupling to inositol phosphates and intracellular Ca2+. PAC1 has been shown previously to be expressed and regulate the growth and proliferation of nonsquamous cell lung cancer cells, as well as breast cancer cell lines. PAC1 is expressed on the HCT8 human colon cancer cell line and is coupled to the activation of both intracellular cAMP and Ca2+ with consequent stimulation of growth. In the current study, we contrast the effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on the HCT8 colon cancer cell lines to the HCT116 and FET cell lines wherein PAC1 is expressed as the SV1 or HIP splice variant and is coupled to the activation only of cAMP but not of intracellular Ca2+. These data indicate that human colon tumor cells express PAC1 and are differentially coupled to intracellular signal transduction molecules. The ability to activate both cAMP and Ca2+ appears to be a prerequisite for activation of tumor proliferation, indicating a potentially important factor in how PACAP potentiates the growth of certain tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742913      PMCID: PMC6707513          DOI: 10.1385/JMN:22:1-2:83

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  16 in total

1.  The two forms of the pituitary adenylate cyclase activating polypeptide (PACAP (1-27) and PACAP (1-38)) interact with distinct receptors on rat pancreatic AR 4-2J cell membranes.

Authors:  P Robberecht; M C Woussen-Colle; P De Neef; P Gourlet; L Buscail; A Vandermeers; M C Vandermeers-Piret; J Christophe
Journal:  FEBS Lett       Date:  1991-07-29       Impact factor: 4.124

2.  A highly sensitive adenylate cyclase assay.

Authors:  Y Salomon; C Londos; M Rodbell
Journal:  Anal Biochem       Date:  1974-04       Impact factor: 3.365

3.  Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38).

Authors:  A Miyata; L Jiang; R D Dahl; C Kitada; K Kubo; M Fujino; N Minamino; A Arimura
Journal:  Biochem Biophys Res Commun       Date:  1990-07-31       Impact factor: 3.575

4.  Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cells.

Authors:  T W Moody; F Zia; A Makheja
Journal:  Peptides       Date:  1993 Mar-Apr       Impact factor: 3.750

5.  The 38-amino acid form of pituitary adenylate cyclase-activating polypeptide stimulates dual signaling cascades in PC12 cells and promotes neurite outgrowth.

Authors:  P J Deutsch; Y Sun
Journal:  J Biol Chem       Date:  1992-03-15       Impact factor: 5.157

6.  Pituitary adenylate cyclase activating peptide and vasoactive intestinal polypeptide: differentiation effects on human neuroblastoma NB-OK-1 cells.

Authors:  M Hoshino; M Li; L Q Zheng; M Suzuki; T Mochizuki; N Yanaihara
Journal:  Neurosci Lett       Date:  1993-09-03       Impact factor: 3.046

7.  Characterization of the pharmacology, signal transduction and internalization of the fluorescent PACAP ligand, fluor-PACAP, on NIH/3T3 cells expressing PAC1.

Authors:  P M Germano; J Stalter; S V Le; M Wu; D J Yamaguchi; D Scott; J R Pisegna
Journal:  Peptides       Date:  2001-06       Impact factor: 3.750

8.  PAC1 and PACAP expression, signaling, and effect on the growth of HCT8, human colonic tumor cells.

Authors:  Sang V Le; Dean J Yamaguchi; Craig A McArdle; Ken Tachiki; Joseph R Pisegna; Patrizia Germano
Journal:  Regul Pept       Date:  2002-11-15

9.  PACAP-27 tyrosine phosphorylates mitogen activated protein kinase and increases VEGF mRNAs in human lung cancer cells.

Authors:  Terry W Moody; Julius Leyton; Marchessini Casibang; Joseph Pisegna; Robert T Jensen
Journal:  Regul Pept       Date:  2002-11-15

10.  Pituitary adenylate cyclase activating peptide receptors regulate the growth of non-small cell lung cancer cells.

Authors:  F Zia; M Fagarasan; K Bitar; D H Coy; J R Pisegna; S A Wank; T W Moody
Journal:  Cancer Res       Date:  1995-11-01       Impact factor: 12.701

View more
  9 in total

Review 1.  Genomic biomarkers for molecular imaging: predicting the future.

Authors:  Mathew L Thakur
Journal:  Semin Nucl Med       Date:  2009-07       Impact factor: 4.446

Review 2.  Alternative splicing of pre-mRNA in cancer: focus on G protein-coupled peptide hormone receptors.

Authors:  Meike Körner; Laurence J Miller
Journal:  Am J Pathol       Date:  2009-07-02       Impact factor: 4.307

3.  Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation.

Authors:  Kaijun Zhang; Mohan R Aruva; Nylla Shanthly; Christopher A Cardi; Chirag A Patel; Satish Rattan; Gregory Cesarone; Eric Wickstrom; Mathew L Thakur
Journal:  Regul Pept       Date:  2007-07-06

4.  MiR-34c-3p suppresses the proliferation and invasion of non-small cell lung cancer (NSCLC) by inhibiting PAC1/MAPK pathway.

Authors:  Yuan-Li Zhou; You-Jun Xu; Chuan-Wu Qiao
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

Review 5.  Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-02       Impact factor: 3.243

Review 6.  Precision Medicine for CRC Patients in the Veteran Population: State-of-the-Art, Challenges and Research Directions.

Authors:  Shyam S Mohapatra; Surinder K Batra; Srinivas Bharadwaj; Michael Bouvet; Bard Cosman; Ajay Goel; Wilma Jogunoori; Michael J Kelley; Lopa Mishra; Bibhuti Mishra; Subhra Mohapatra; Bhaumik Patel; Joseph R Pisegna; Jean-Pierre Raufman; Shuyun Rao; Hemant Roy; Maren Scheuner; Satish Singh; Gitanjali Vidyarthi; Jon White
Journal:  Dig Dis Sci       Date:  2018-03-23       Impact factor: 3.199

7.  PACAP induces signaling and stimulation of 5-hydroxytryptamine release and growth in neuroendocrine tumor cells.

Authors:  Patrizia M Germano; Sandy N Lieu; Janjing Xue; Helen J Cooke; Fievos L Christofi; Yuxin Lu; Joseph R Pisegna
Journal:  J Mol Neurosci       Date:  2009-08-23       Impact factor: 3.444

8.  Alternative Splicing of the Pituitary Adenylate Cyclase-Activating Polypeptide Receptor PAC1: Mechanisms of Fine Tuning of Brain Activity.

Authors:  Janna Blechman; Gil Levkowitz
Journal:  Front Endocrinol (Lausanne)       Date:  2013-05-21       Impact factor: 5.555

Review 9.  Pituitary Adenylate Cyclase-Activating Polypeptide: 30 Years in Research Spotlight and 600 Million Years in Service.

Authors:  Viktoria Denes; Peter Geck; Adrienn Mester; Robert Gabriel
Journal:  J Clin Med       Date:  2019-09-18       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.